Welcome to the spotlight on small molecules immunotherapeutics

Quick access to all the content in the latest MedChemNet spotlight, including expert editorials, peer-reviewing journal content and more.

Go to the profile of MedChemNet
Nov 30, 2017
Upvote 0 Comment

Immunotherapy is starting to emerge as a viable treatment option for indications such as inflammatory disorders and oncology. Although the majority of immunotherapeutics in development are biologics such as antibodies, small molecules may provide some advantages. For example, small molecules may have a lower cost associated with their development and manufacture and they are also more prone to oral bioavailability and, as such, attaining greater exposure to the target.

However, there are some inherent challenges to the design and development of small molecule immunotherapies, such as identifying suitable transient pockets on protein binding particles and their generally hydrophobic nature. These challenges may increase the development timeline as the risk of attrition in the later stages.

This spotlight will provide an inside into the challenges, trends, developments and debates surrounding the development of small molecule immunotherapeutics. We will also explore the current landscape and identify potential future developments.

Visit the spotlight

Editor's picks


Look out for the spotlight survey, coming soon!

Journal articles


Go to the profile of MedChemNet


A network for the medicinal chemistry community, Future Science Group

Your source for the latest news and views from the fields of drug discovery and medicinal chemistry.

No comments yet.